UltraGreen.ai Positioned for Growth with ICG Platform Expansion, BUY Rating and US$1.92 Target Price July 3, 2026

UltraGreen.ai Positioned for Growth with ICG Platform Expansion, BUY Rating and US$1.92 Target Price

Phillip Securities Research has initiated coverage on UltraGreen.ai with a BUY rating and target price of US$1.92, highlighting the company’s transformation from a traditional dye and hardware business into an integrated indocyanine green (ICG) platform. The research firm’s valuation is based on DCF analysis, utilising a 10% WACC and 7 times exit multiple. The company is currently trading at FY26e forward P/E of 15.2 times and EV/EBITDA of 16 times.


Company Overview

UltraGreen.ai operates in the fluorescence-guided surgery market, providing ICG dyes and near-infrared imaging hardware to healthcare providers. The company is expanding its business model beyond commodity products to become a comprehensive ICG platform provider, incorporating data analytics and software solutions.


Market Opportunity and Penetration Drivers

Strong market tailwinds are driving greater ICG penetration across both established and emerging surgical procedures globally. Currently, ICG penetration across surgical procedures remains in the low double-digits, with the exception of choroid diagnostics. However, penetration rates are expected to increase by double digits across the majority of procedures using fluorescence-guided surgery by 2028.

The primary driver for this expansion is the growing adoption of ICG as a standard of care, with major surgical societies incorporating ICG into their clinical guidelines. A significant catalyst for UltraGreen.ai will be the expiry of Novadaq’s Breast Sentinel Lymph Node exclusivity in June 2026, enabling the company to file for US approval and potentially capture a US$66.2 million market opportunity at full ICG penetration.


Platform Business Transformation

UltraGreen.ai is strategically expanding from its traditional dye plus hardware business into an integrated ICG platform through its PerfusionWorks quantification software and cloud platform. The PerfusionWorks software is expected to receive Europe MDR regulatory approval by 2H26, with subsequent US FDA filing planned to use the European dataset.

Notably, the software is camera agnostic and can be used with competitors’ imaging hardware, making every near-infrared-capable imaging device a potential customer. This approach addresses the critical obstacle of subjectivity in fluorescence imaging assessment by providing objective and reproducible perfusion data, thereby facilitating standardisation required for broader ICG adoption as a standard of care.


Growth Strategy and Financial Position

The company maintains a robust financial position, with net cash of US$176.1 million and is pursuing growth initiatives worth approximately US$150 million in potential investments or acquisitions across API suppliers, distributors, and lyophilisation companies. UltraGreen.ai also plans to transition from distributor models to direct sales in select markets, reducing distributor fees and enabling direct hospital relationships. This would support the bundling ICG vials with NIR cameras and cross-selling PerfusionWorks software. The research forecasts a 2-year earnings CAGR of 18.6%.


Frequently Asked Questions

Q: What is Phillip Securities Research's recommendation and target price for UltraGreen.ai?

A: Phillip Securities Research has initiated coverage with a BUY rating and a target price of US$1.92, based on DCF analysis using a 10% WACC and 7 times exit multiple.

Q: What is the current ICG penetration rate across surgical procedures?

A: ICG penetration across surgical procedures remains in the low double-digits globally, except for choroid diagnostics. Penetration rates are expected to increase by double digits across the majority of procedures using fluorescence-guided surgery by 2028.

Q: When will UltraGreen.ai be able to enter the US Breast Sentinel Lymph Node market?

A: Following the expiry of Novadaq's Breast SLN exclusivity in June 2026, UltraGreen.ai will be eligible to file for Breast SLN indication in the US for the first time. This represents a US$66.2 million market opportunity at full penetration.

Q: What is PerfusionWorks and when will it receive regulatory approval?

A: PerfusionWorks is UltraGreen.ai's quantification software and cloud platform that provides objective and reproducible perfusion data. It is expected to receive Europe MDR regulatory approval by 2H26, followed by US FDA filing.

Q: How much is UltraGreen.ai planning to invest in growth initiatives?

A: The company is open to approximately US$150 million in potential investments or acquisitions across API suppliers, distributors, and lyophilisation companies to build supply chain resilience and reduce costs.

Q: What is UltraGreen.ai's current financial position?

A: UltraGreen.ai maintains a net cash position of US$176.1 million and is currently trading at FY26e forward P/E of 15.2 times and EV/EBITDA of 16 times.

Q: What is the forecasted earnings growth for UltraGreen.ai?

A: Phillip Securities Research forecasts a 2-year earnings CAGR of 18.6% for UltraGreen.ai.

Q: What advantage does the PerfusionWorks software have in the market?

A: The PerfusionWorks software is camera agnostic and can be used with competitors' imaging hardware, making every near-infrared-capable imaging device a potential customer and addressing the subjectivity obstacle in fluorescence imaging assessment.

 

This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.

 

Disclaimer

These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.

Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.

Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

This advertisement has not been reviewed by the Monetary Authority of Singapore.

About the author

UltraGreen.ai Positioned for Growth with ICG Platform Expansion, BUY Rating and US$1.92 Target Price

Hashim Osman

Hashim graduated from the National University of Singapore with a degree in Business Administration.

Related Articles

Software Sector Remains Resilient Amid AI Disruption Concerns Software Sector Remains Resilient Amid AI Disruption Concerns
Thai Beverage Navigates Challenging Consumer Environment with Strategic Adaptation, Maintains BUY Rating at S$0.53 Thai Beverage Navigates Challenging Consumer Environment with Strategic Adaptation, Maintains BUY Rating at S$0.53
Micron Technology Benefits from AI Memory Demand and Tight Supply Micron Technology Benefits from AI Memory Demand and Tight Supply
Save on Brokerage Fees When Trading with CPF/SRS Funds Save on Brokerage Fees When Trading with CPF/SRS Funds
Market Journal

Join Events & Seminars

Learn best practices and latest market outlook from experts and special guests

Market Journal

Hear & Ask our Experts

Join live weekly market calls

Market Journal

Read Popular News & Reports, Technical Pulses

at www.poems.com.sg/stock-research

Market Journal

Subscribe to our YouTube Channel

New video every week

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com